Vanguard Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$329M Buy
15,264,240
+61,006
+0.4% +$1.32M 0.01% 1265
2025
Q1
$253M Buy
15,203,234
+1,255,594
+9% +$20.9M ﹤0.01% 1365
2024
Q4
$256M Buy
13,947,640
+104,444
+0.8% +$1.92M ﹤0.01% 1423
2024
Q3
$213M Buy
13,843,196
+131,065
+1% +$2.02M ﹤0.01% 1513
2024
Q2
$223M Buy
13,712,131
+413,590
+3% +$6.72M ﹤0.01% 1439
2024
Q1
$246M Sell
13,298,541
-97,468
-0.7% -$1.8M ﹤0.01% 1388
2023
Q4
$419M Sell
13,396,009
-220,731
-2% -$6.91M 0.01% 1074
2023
Q3
$284M Sell
13,616,740
-238,106
-2% -$4.96M 0.01% 1241
2023
Q2
$332M Buy
13,854,846
+176,037
+1% +$4.22M 0.01% 1179
2023
Q1
$257M Buy
13,678,809
+399,034
+3% +$7.51M 0.01% 1319
2022
Q4
$211M Buy
13,279,775
+354,134
+3% +$5.64M 0.01% 1397
2022
Q3
$211M Buy
12,925,641
+525,048
+4% +$8.59M 0.01% 1356
2022
Q2
$175M Sell
12,400,593
-180,221
-1% -$2.54M ﹤0.01% 1510
2022
Q1
$305M Buy
12,580,814
+265,448
+2% +$6.43M 0.01% 1284
2021
Q4
$287M Buy
12,315,366
+186,100
+2% +$4.34M 0.01% 1375
2021
Q3
$201M Buy
12,129,266
+610,949
+5% +$10.1M 0.01% 1606
2021
Q2
$281M Buy
11,518,317
+657,142
+6% +$16M 0.01% 1410
2021
Q1
$280M Buy
10,861,175
+255,402
+2% +$6.59M 0.01% 1367
2020
Q4
$567M Buy
10,605,773
+236,083
+2% +$12.6M 0.02% 815
2020
Q3
$428M Sell
10,369,690
-291,729
-3% -$12M 0.01% 839
2020
Q2
$517M Sell
10,661,419
-321,618
-3% -$15.6M 0.02% 745
2020
Q1
$464M Buy
10,983,037
+366,424
+3% +$15.5M 0.02% 692
2019
Q4
$454M Buy
10,616,613
+105,989
+1% +$4.53M 0.02% 869
2019
Q3
$378M Buy
10,510,624
+1,005,542
+11% +$36.2M 0.01% 943
2019
Q2
$254M Buy
9,505,082
+7,440
+0.1% +$199K 0.01% 1211
2019
Q1
$255M Sell
9,497,642
-644,022
-6% -$17.3M 0.01% 1185
2018
Q4
$164M Buy
10,141,664
+1,312,046
+15% +$21.2M 0.01% 1372
2018
Q3
$183M Buy
8,829,618
+155,172
+2% +$3.22M 0.01% 1448
2018
Q2
$132M Buy
8,674,446
+518,282
+6% +$7.91M 0.01% 1633
2018
Q1
$183M Buy
8,156,164
+170,967
+2% +$3.84M 0.01% 1340
2017
Q4
$240M Buy
7,985,197
+213,689
+3% +$6.43M 0.01% 1183
2017
Q3
$293M Buy
7,771,508
+166,903
+2% +$6.29M 0.01% 1015
2017
Q2
$212M Buy
7,604,605
+134,820
+2% +$3.76M 0.01% 1193
2017
Q1
$257M Buy
7,469,785
+348,141
+5% +$12M 0.01% 1054
2016
Q4
$205M Buy
7,121,644
+252,648
+4% +$7.29M 0.01% 1142
2016
Q3
$219M Buy
6,868,996
+500,036
+8% +$15.9M 0.01% 1054
2016
Q2
$207M Buy
6,368,960
+49,421
+0.8% +$1.6M 0.01% 1039
2016
Q1
$177M Buy
6,319,539
+717,883
+13% +$20.1M 0.01% 1095
2015
Q4
$200M Buy
5,601,656
+148,646
+3% +$5.3M 0.01% 1012
2015
Q3
$180M Buy
5,453,010
+150,048
+3% +$4.96M 0.01% 1053
2015
Q2
$222M Buy
5,302,962
+171,603
+3% +$7.19M 0.02% 992
2015
Q1
$167M Buy
5,131,359
+249,158
+5% +$8.12M 0.01% 1138
2014
Q4
$155M Buy
4,882,201
+51,584
+1% +$1.64M 0.01% 1124
2014
Q3
$120M Buy
4,830,617
+965
+0% +$23.9K 0.01% 1227
2014
Q2
$109M Buy
4,829,652
+39,758
+0.8% +$898K 0.01% 1340
2014
Q1
$117M Buy
4,789,894
+474,281
+11% +$11.5M 0.01% 1256
2013
Q4
$108M Buy
4,315,613
+438,600
+11% +$11M 0.01% 1268
2013
Q3
$107M Buy
3,877,013
+954,544
+33% +$26.2M 0.01% 1200
2013
Q2
$53M Buy
+2,922,469
New +$53M 0.01% 1598